Lonsurf® is the commercial brand name of Trifluridine and Tipiracil Tablets, an orally active fixed-combination anticancer agent developed by Japan Taiho Pharmaceutical. Trifluridine inserts into tumor DNA to block cancer cell proliferation, and tipiracil inhibits trifluridine metabolic breakdown to sustain…
Livtencity® is the commercial brand name of Maribavir Tablets, an orally active anti-cytomegalovirus agent developed by Takeda Pharmaceutical. It inhibits CMV UL97 kinase to block viral DNA replication and virion maturation against drug-resistant cytomegalovirus. Main IndicationsTreatment of refractory or drug-resistant…
Dovato® is the commercial brand name of Lamivudine and Dolutegravir Sodium Tablets, an orally active dual-agent fixed-dose anti-HIV combination developed by ViiV Healthcare. Dolutegravir sodium inhibits HIV integrase to prevent viral DNA integration into host genome, while lamivudine blocks HIV…
Biktarvy® is the commercial brand name of Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets, an orally active single-tablet fixed-dose combination anti-HIV agent developed by Gilead Sciences. Bictegravir inhibits HIV integrase to block viral gene integration, while emtricitabine and tenofovir…
Epclusa® is the commercial brand name of Sofosbuvir and Velpatasvir Tablets, an oral fixed-dose combination anti-hepatitis C medicine developed by Gilead Sciences. Sofosbuvir inhibits HCV NS5B polymerase to block viral nucleic acid synthesis, while velpatasvir suppresses NS5A protein to hinder…
Harvoni® is the commercial brand name of Ledipasvir and Sofosbuvir Tablets, an oral fixed-dose combination anti-HCV drug developed by Gilead Sciences. Ledipasvir inhibits HCV NS5A protein while sofosbuvir blocks viral NS5B polymerase, jointly suppressing hepatitis C virus replication. Main IndicationsTreatment…
Ganovo® is the commercial brand name of Danoprevir Sodium Tablets, an orally active HCV NS3/4A protease inhibitor developed by Ascletis Pharma. It blocks hepatitis C virus protease to hinder viral protein cleavage and suppress HCV replication. Main IndicationsUsed in combination…
Vemlidy® is the commercial brand name of Tenofovir Alafenamide Fumarate Tablets, an orally active nucleotide reverse transcriptase inhibitor developed by Gilead Sciences. It inhibits hepatitis B virus replication by blocking viral reverse transcriptase to suppress HBV DNA synthesis. Main IndicationsTreatment…
Deltyba® is the commercial brand name of Delamanid Tablets, an orally active nitroimidazole anti-tuberculosis drug developed by Otsuka Pharmaceutical. It interferes with mycobacterial cell wall synthesis to exert bactericidal activity against drug-resistant Mycobacterium tuberculosis. Main IndicationsCombined treatment for adult patients…
Sirturo® is the commercial brand name of Bedaquiline Fumarate Tablets, an orally active diarylquinoline anti-tuberculosis agent developed by Janssen. It inhibits mycobacterial ATP synthase to block bacterial energy synthesis and exert bactericidal activity against multidrug-resistant Mycobacterium tuberculosis. Main IndicationsCombination therapy…